Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    Phase 1 Trial Begins for IV Version of Smallpox Drug

    By Global Biodefense StaffMarch 23, 2016
    Biodefense Medical Countermeasures
    Share
    Facebook LinkedIn Reddit Email

    Biodefense Medical CountermeasuresBacked by funding from the Biomedical Advanced Research and Development Authority (BARDA), SIGA Technologies is initiating a Phase I single ascending dose clinical study for the intravenous formulation of the TPOXX (tecovirimat) for the treatment of orthopoxvirus disease, including smallpox.

    The oral version of the novel small-molecule drug is being delivered to the Strategic National Stockpile under Project BioShield. SIGA is developing the IV formulation as an alternative treatment for those individuals who suffer from dysphagia or seriously ill individuals who are hospitalized and cannot swallow oral capsules.

    Screening of subjects began on March 7, 2016 and the first subject was expected to be enrolled and dosed on March 21, 2016. This study will evaluate safety data as well as pharmacokinetic data to aid in the development of a protocol for the next Phase I clinical trial in the IV program, a multiple ascending dose safety and pharmacokinetic trial.

    “This collaboration with BARDA on an IV formulation is an important step toward realizing the full capability of TPOXX,” said Dr. Eric Rose, SIGA’s Chief Executive Officer. Dr. Rose further noted that “this trial advances our efforts to ensure better protection of Americans from a smallpox outbreak.”

    Previous laboratory and animal tests suggest that tecovirimat blocks the ability of the virus to spread, thus preventing disease symptoms in animal models of smallpox in which tecovirimat has been tested to date. Laboratory experiments also suggest that tecovirimat may function without compromising acquisition of protective immunity.

    Source: SIGA Technologies press release, adapted.

    Animal Models ASPR BARDA HHS Poxviruses Smallpox
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleFDA Approves New Injection for Inhalational Anthrax
    Next Article Thermostable Ricin Vaccine Gets Another Funding Boost

    Related Stories

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Case Study: Fatal Avian Influenza Infection in Cat in Poland

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.